BACKGROUND: We conducted a post-hoc analysis of the Long-Acting MethylpheniDate in
Adult attention-deficit hyperactivity disorder (LAMDA) study to investigate predictors of …

Objective. OROS methylphenidate HCL (MPH) is a recently developed long-acting stimulant
medication used to treat attention-deficit/hyperactivity disorder (ADHD). This study was …

Objective: To assess the efficacy and safety of OROS methylphenidate (Concerta; McNeil
Pediatrics Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc, Titusville, NJ) in the …

Abstract Background and Objectives In the management of attention-deficit hyperactivity
disorder (ADHD) in adults it is important to recognize that individual patients respond to a …

This community-based study was designed to evaluate treatment outcomes with OROS®
methylphenidate (MPH) and atomoxetine in children with attentiondeficit/hyperactivity …

The objective of this study was to compare the single‐dose pharmacokinetics of multilayer‐
release and immediate‐release methylphenidate in children with attention …

Purpose Current literature on the safety and efficacy of various intermediate-and long-acting
preparations of methylphenidate and dexmethylphenidate for pediatric attention …

Attention deficit hyperactivity disorder (ADHD) is the most commonly diagnosed
neurobehavioural disorder in childhood, affecting over 5% of children worldwide. As well as …

Introduction There are limited head-to-head data comparing the efficacy of long-acting
amfetamine-and methylphenidate-based psychostimulants as treatments for individuals with …

More than 50 years ago, methylphenidate immediate-release (MPH-IR) was found to be
effective in relieving symptoms of attention-deficit/hyperactivity disorder. Although the exact …